Savant Capital LLC Has $365,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Savant Capital LLC trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 93.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,571 shares of the company’s stock after selling 34,088 shares during the period. Savant Capital LLC’s holdings in Neurocrine Biosciences were worth $365,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. AlTi Global Inc. boosted its stake in shares of Neurocrine Biosciences by 1.0% during the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after buying an additional 70 shares during the last quarter. Huntington National Bank raised its holdings in shares of Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after purchasing an additional 76 shares during the period. Perigon Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 3.1% in the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after purchasing an additional 78 shares during the period. Signaturefd LLC raised its holdings in shares of Neurocrine Biosciences by 4.5% in the 4th quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock valued at $273,000 after purchasing an additional 83 shares during the period. Finally, Bessemer Group Inc. raised its holdings in shares of Neurocrine Biosciences by 3.4% in the 3rd quarter. Bessemer Group Inc. now owns 2,871 shares of the company’s stock valued at $402,000 after purchasing an additional 95 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Kevin Charles Gorman sold 245,088 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total value of $37,824,431.04. Following the transaction, the director owned 511,293 shares in the company, valued at approximately $78,907,848.69. This represents a 32.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David W. Boyer sold 3,888 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $156.64, for a total transaction of $609,016.32. Following the completion of the transaction, the insider owned 7,799 shares in the company, valued at approximately $1,221,635.36. This trade represents a 33.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 328,984 shares of company stock worth $50,986,985 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Wolfe Research assumed coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price on the stock. Royal Bank Of Canada upped their target price on shares of Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a report on Friday, May 29th. Zacks Research raised shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Finally, Morgan Stanley upped their target price on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $187.52.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $163.88 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $169.57. The firm has a market cap of $16.48 billion, a P/E ratio of 25.25, a price-to-earnings-growth ratio of 1.26 and a beta of 0.40. The firm’s 50-day simple moving average is $142.73 and its 200 day simple moving average is $139.71.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.